Relief Therapeutics Holding AG (0QKQ.L)

CHF 2.4

(-2.44%)

Net Debt Summary of Relief Therapeutics Holding AG

Relief Therapeutics Holding AG's latest annual net debt in 2023 was -10.24 Million CHF , up 31.21% from previous year.
Relief Therapeutics Holding AG's latest quarterly net debt in 2024 Q2 was -8.31 Million CHF , down 0.0% from previous quarter.
Relief Therapeutics Holding AG reported annual net debt of -14.89 Million CHF in 2022, up 63.22% from previous year.
Relief Therapeutics Holding AG reported annual net debt of -40.49 Million CHF in 2021, up 4.18% from previous year.
Relief Therapeutics Holding AG reported quarterly net debt of -8.24 Million CHF for 2023 Q2, down 0.0% from previous quarter.
Relief Therapeutics Holding AG reported quarterly net debt of -10.24 Million CHF for 2023 FY, up 31.21% from previous quarter.

Annual Net Debt Chart of Relief Therapeutics Holding AG (2023 - 2007)

Historical Annual Net Debt of Relief Therapeutics Holding AG (2023 - 2007)

Year	Net Debt	Net Debt Growth
2023	-10.24 Million CHF	31.21%
2022	-14.89 Million CHF	63.22%
2021	-40.49 Million CHF	4.18%
2020	-42.26 Million CHF	-2725.03%
2019	1.61 Million CHF	104.31%
2018	788 Thousand CHF	-10.15%
2017	877 Thousand CHF	81.2%
2016	484 Thousand CHF	-88.67%
2015	4.27 Million CHF	486.58%
2014	-1.1 Million CHF	-114.72%
2013	7.5 Million CHF	211.71%
2012	2.4 Million CHF	313.51%
2011	-1.12 Million CHF	43.67%
2010	-2 Million CHF	53.45%
2009	-4.3 Million CHF	68.31%
2008	-13.56 Million CHF	-87.52%
2007	-7.23 Million CHF	0.0%

Year	Net Debt	Net Debt Growth
2024 Q2	-8.31 Million CHF	0.0%
2023 Q2	-8.24 Million CHF	0.0%
2023 FY	-10.24 Million CHF	31.21%
2023 Q4	-10.24 Million CHF	0.0%
2022 Q4	-14.89 Million CHF	0.0%
2022 Q2	-27.04 Million CHF	0.0%
2022 FY	-14.89 Million CHF	63.22%
2021 Q2	-15.21 Million CHF	0.0%
2021 FY	-40.49 Million CHF	4.18%
2021 Q4	-40.49 Million CHF	0.0%
2020 Q2	1.74 Million CHF	0.0%
2020 FY	-42.26 Million CHF	-2725.03%
2020 Q4	-42.26 Million CHF	0.0%
2019 Q4	1.61 Million CHF	0.0%
2019 FY	1.61 Million CHF	104.31%
2019 Q2	1.27 Million CHF	0.0%
2018 FY	788 Thousand CHF	-10.15%
2018 Q2	5.25 Million CHF	0.0%
2018 Q4	4.37 Million CHF	0.0%
2017 Q4	877 Thousand CHF	0.0%
2017 FY	877 Thousand CHF	81.2%
2017 Q2	655 Thousand CHF	0.0%
2016 Q4	484 Thousand CHF	0.0%
2016 FY	484 Thousand CHF	-88.67%
2016 Q2	3.26 Million CHF	0.0%
2015 Q4	4.27 Million CHF	0.0%
2015 Q2	1.8 Million CHF	0.0%
2015 FY	4.27 Million CHF	486.58%
2014 Q4	-1.1 Million CHF	0.0%
2014 Q2	7.37 Million CHF	0.0%
2014 FY	-1.1 Million CHF	-114.72%
2013 FY	7.5 Million CHF	211.71%
2013 Q2	2.18 Million CHF	0.0%
2013 Q4	7.5 Million CHF	0.0%
2012 Q2	1.6 Million CHF	0.0%
2012 Q4	2.4 Million CHF	0.0%
2012 FY	2.4 Million CHF	313.51%
2011 Q4	-1.12 Million CHF	0.0%
2011 FY	-1.12 Million CHF	43.67%
2011 Q2	-3.92 Million CHF	0.0%
2010 Q2	-2.63 Million CHF	0.0%
2010 FY	-2 Million CHF	53.45%
2010 Q4	-2 Million CHF	0.0%
2009 FY	-4.3 Million CHF	68.31%
2009 Q4	-4.3 Million CHF	0.0%
2009 Q2	-7.22 Million CHF	0.0%
2008 FY	-13.56 Million CHF	-87.52%
2008 Q4	-13.56 Million CHF	0.0%
2007 FY	-7.23 Million CHF	0.0%

Peer Net Debt Comparison of Relief Therapeutics Holding AG

Name	Net Debt	Net Debt Difference
Tecan Group AG	183.12 Million CHF	105.594%
Santhera Pharmaceuticals Holding AG	-5.3 Million CHF	-93.011%
Basilea Pharmaceutica AG	116.11 Million CHF	108.823%
Bachem Holding AG	-157.32 Million CHF	93.488%
Siegfried Holding AG	468.63 Million CHF	102.186%
Molecular Partners AG	-183.23 Million CHF	94.409%